CYPH
Bearish signalScored 2026-10-01 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Cypherpunk Technologies Inc.
- Nom
- Cypherpunk Technologies Inc.
- Secteur
- Financial Services
- Industrie
- Asset Management
- Bourse
- NASDAQ
- Capitalisation
- $305.0M
- Employés
- 6
- PDG
- Douglas E. Onsi
- Site web
- https://www.cypherpunk.com
- Marché
- APLMASBPATHABCTXCRISCTXR
Cypherpunk Technologies Inc. is a privacy-focused technology company that combines a digital asset treasury strategy centered on Zcash (ZEC) with the development of novel cancer therapies through its subsidiary. The company's mission is to advance technologies that guarantee privacy for individuals on the internet, with a primary focus on investing in, accelerating the adoption of, and strengthening the ecosystem of Zcash, a privacy-preserving digital currency.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 238 750 titres (~888 900,00 $ US)
- Insiders
- Oei Khing DjienMartin Patricia A.Dietz Thomas John
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$888,900
Avg sell (VWAP, 90d window) $3.72 vs last close $3.17 (-14.9%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-25
- Liquidity
- Liquid $62,634,971/day · 20d vol
- Last synced
-
2026-10-05 21:10:17
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-25 | Oei Khing Djien | Sell · S | 168,750 | $3.92 | $661,500 | Form 4 |
| 2026-09-23 | Martin Patricia A. | Sell · S | 50,000 | $3.86 | $193,000 | Form 4 |
| 2026-08-26 | Dietz Thomas John | Sell · S | 20,000 | $1.72 | $34,400 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-01 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
CYPH presents a deeply concerning profile: zero revenue, negative operating cash flows, and a massive headcount decline paint the picture of a non-operational shell with no credible path to profitability.
The first sentence of the analysis written for CYPH on 2026-10-01 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 35.56 · operating margin 0.0%
Suggested stop 1.78, nearest stored support minus 0.5 ATR(43.8% under the last close). Reward/risk to the next stored resistance is 0.04. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -2704.7% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | -2702.7% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -2761.7% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -2707.4% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -2705.8% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -2705.8% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | -2705.8% | |
| Current Ratio | 35.560 | 3.413 | 5.645 | 17.067 | 11.703 | |
| Quick Ratio | 35.560 | 3.413 | 5.645 | 16.619 | 11.703 | |
| Solvency Ratio | 0.498 | -4.799 | -6.385 | -15.825 | -4.046 | |
| Cash Ratio | 3.079 | 3.357 | 5.569 | 6.733 | 11.507 | |
| Price To Earnings Ratio | 15.912 | -1.591 | -1.040 | -0.934 | -6.850 | |
| Price To Earnings Growth Ratio | -0.153 | 0.029 | 0.060 | -0.491 | -3.532 | |
| Forward Price To Earnings Growth Ratio | -0.153 | 0.029 | 0.060 | -0.491 | -3.532 | |
| Price To Earnings Diluted Ratio | 17.009 | -1.591 | -1.040 | -0.934 | -6.850 | |
| Price To Earnings Diluted Growth Ratio | -0.164 | 0.029 | 0.060 | -0.491 | -3.532 | |
| Price To Book Ratio | 0.500 | 3.086 | 1.407 | 0.933 | 2.577 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 185.383 | |
| Price To Free Cash Flow Ratio | -1.748 | -1.793 | -1.935 | -1.039 | -7.909 | |
| Price To Operating Cash Flow Ratio | -1.748 | -1.793 | -1.935 | -1.039 | -7.909 | |
| Debt To Assets Ratio | 0.000 | 0.005 | 0.004 | 0.009 | 0.004 | |
| Debt To Equity Ratio | 0.000 | 0.008 | 0.004 | 0.010 | 0.004 | |
| Debt To Capital Ratio | 0.000 | 0.008 | 0.004 | 0.009 | 0.004 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.063 | 1.402 | 1.211 | 1.063 | 1.093 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.017 | |
| Operating Cash Flow Ratio | -9.632 | -4.284 | -3.449 | -15.729 | -3.520 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -23.438 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | -1,741.458 | 0.000 | 0.000 | -1,009.741 | -988.220 | |
| Interest Coverage Ratio | -1,522.500 | 0.000 | 0.000 | -1,051.167 | -1,010.390 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1,155.316 | -226.688 | -166.996 | -93.595 | -74.962 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.717 | -0.913 | -0.176 | -0.561 | -4.036 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-20.0% |
| Ebit Margin | 0.0% | 0.0% | ▲540.9% |
| Ebitda Margin | 0.0% | 0.0% | ▲540.5% |
| Operating Profit Margin | 0.0% | 0.0% | ▲552.4% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲541.5% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲541.2% |
| Net Profit Margin | 0.0% | 0.0% | ▲541.2% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲541.2% |
| Current Ratio | 35.560 | ▲32.147 | ▲20.882 |
| Quick Ratio | 35.560 | ▲32.147 | ▲20.972 |
| Solvency Ratio | 0.498 | ▲5.297 | ▲6.610 |
| Cash Ratio | 3.079 | ▼-0.278 | ▼-2.970 |
| Price To Earnings Ratio | 15.912 | ▲17.503 | ▲14.813 |
| Price To Earnings Growth Ratio | -0.153 | ▼-0.182 | ▲0.664 |
| Forward Price To Earnings Growth Ratio | -0.153 | ▼-0.182 | ▲0.664 |
| Price To Earnings Diluted Ratio | 17.009 | ▲18.600 | ▲15.690 |
| Price To Earnings Diluted Growth Ratio | -0.164 | ▼-0.193 | ▲0.655 |
| Price To Book Ratio | 0.500 | ▼-2.586 | ▼-1.201 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-37.077 |
| Price To Free Cash Flow Ratio | -1.748 | ▲0.046 | ▲1.137 |
| Price To Operating Cash Flow Ratio | -1.748 | ▲0.046 | ▲1.137 |
| Debt To Assets Ratio | 0.000 | ▼-0.005 | ▼-0.004 |
| Debt To Equity Ratio | 0.000 | ▼-0.007 | ▼-0.005 |
| Debt To Capital Ratio | 0.000 | ▼-0.007 | ▼-0.005 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.063 | ▼-0.339 | ▼-0.103 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.004 |
| Operating Cash Flow Ratio | -9.632 | ▼-5.348 | ▼-2.309 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲4.688 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | 0.000 |
| Debt Service Coverage Ratio | -1741.458 | ▼-1741.458 | ▼-993.575 |
| Interest Coverage Ratio | -1522.500 | ▼-1522.500 | ▼-805.689 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -1155.316 | ▼-928.628 | ▼-811.804 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.717 | ▼-0.803 | ▼-0.236 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $76.7M | $108.1M | $84.6M | $51.0M | $278.1M | |
| Enterprise value | $62.7M | $61.2M | $14.3M | $30.5M | $163.6M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 109.08x | |
| EV / Op. cash flow | -1.43x | -1.01x | -0.33x | -0.62x | -4.65x | |
| EV / Free cash flow | -1.43x | -1.01x | -0.33x | -0.62x | -4.65x | |
| EV / EBITDA | -1.72x | -0.91x | -0.18x | -0.56x | -4.04x | |
| Net debt / EBITDA | 0.38x | 0.70x | 0.87x | 0.38x | 2.82x | |
| Current ratio | 35.56x | 3.41x | 5.64x | 17.07x | 11.70x | |
| Income quality | -9.11x | 0.89x | 0.54x | 0.90x | 0.87x | |
| Graham number | $2 | — | — | — | — | |
| Graham net-net | $2 | $1 | $3 | $4 | $12 | |
| Tax burden | 47.9% | 100.9% | 100.0% | 100.3% | 99.9% | |
| Interest burden | -27.6% | 100.0% | 100.0% | 100.1% | 100.1% | |
| Working capital | $157.5M | $34.0M | $58.9M | $50.1M | $106.9M | |
| Invested capital | $157.6M | $34.2M | $59.2M | $50.5M | $107.4M | |
| Return on assets | 3.0% | -137.5% | -111.8% | -94.0% | -34.4% | |
| Operating ROA | -34.4% | -114.9% | -133.0% | -64.5% | -44.0% | |
| Return on tangible assets | 3.0% | -137.5% | -111.8% | -94.0% | -34.4% | |
| Return on equity | 3.1% | -192.7% | -135.4% | -99.9% | -37.6% | |
| Return on invested capital | -11.0% | -198.4% | -144.1% | -102.8% | -38.2% | |
| Return on capital employed | -23.0% | -199.9% | -144.7% | -103.3% | -38.4% | |
| Earnings yield | 6.3% | -62.5% | -96.2% | -107.1% | -14.6% | |
| Free cash flow yield | -57.2% | -55.8% | -51.7% | -96.2% | -12.6% | |
| Capex / Op. cash flow | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 717.7% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 2144.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 232.1% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 289d | |
| Days payables outstanding | 0d | 0d | 5526d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 289d | |
| Cash conversion cycle | 0d | 0d | -5526d | 0d | 289d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-22 Cypherpunk Technologies Appoints Amanda Fabiano to Board of Directors Veteran mining executive brings operational depth from Nakamoto, TeraWulf, Galaxy, and Fidelity as Cypherpunk launches 4.2 GSol/s Zcash mining fleet Cypherpunk Mining generated 3,023.13 ZEC in first weeks of operation; Added to Treasury CAMBRIDGE, Mass., Sept. 22, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) ("Cypherpunk"), a privacy technology company, today announced the appointment of Amanda Fabiano to its Board of Directors.
- 2026-08-25 Cypherpunk Technologies Looks Fully Valued After Zcash-Fueled Surge Cypherpunk Technologies Inc. now holds a significant ZEC treasury and has acquired a major Zcash mining operation, boosting its asset value. Recent ZEC price surges and the launch of the Zcash ETF have driven CYPH''s valuation, but the stock''s rapid rise has consumed much of its immediate upside. CYPH''s fully diluted share count and complex capital structure mean headline market cap underestimates the price investors are paying for exposure.
- 2026-08-18 Cypherpunk Technologies Launches World''s Largest Zcash Mining Fleet Equity-based transaction with Winklevoss Capital activates 4.2 GSol/s of live, U.S.-based hashrate; approximately 18% of the Zcash network; Industry veteran Kevin Zhang joins as Head of Mining CAMBRIDGE, Mass., Aug. 18, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) ("Cypherpunk") today announced the launch of Cypherpunk Mining, which is now the largest Zcash mining fleet in the world, through a $33.33 million equity-based transaction with Winklevoss Capital.
- 2026-08-12 Cypherpunk Technologies Reports Second Quarter 2026 Financial Results CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the second quarter ended June 30, 2026.
- 2026-08-12 Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research Peer-reviewed analyses establish baseline plasma DKK1 as a continuous quantitative biomarker predicting deepening sirexatamab benefit in 2L mCRC patients In DKK1-high 2L mCRC patients, sirexatamab improved response, progression-free survival, and overall survival when added to bevacizumab and chemotherapy CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Leap Therapeutics, Inc., the biotechnology subsidiary of Cypherpunk Technologies Inc. (Nasdaq: CYPH), today announced the publication of results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research.